These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 7546811)

  • 61. Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
    Frattola L; Albizzati MG; Bassi S; Spano PF; Trabucchi M
    Adv Biochem Psychopharmacol; 1980; 23():381-6. PubMed ID: 6446848
    [No Abstract]   [Full Text] [Related]  

  • 62. Levodopa-carbidopa.
    Guttridge D
    Aust Nurses J; 1980 May; 9(10):28-9. PubMed ID: 6901482
    [No Abstract]   [Full Text] [Related]  

  • 63. [The additive effect of amantadine hydrochloride (Symmetrel) on parkinsonian patients receiving levodopa treatment (author's transl)].
    Shiozawa R; Kase M; Kuroiwa Y; Narabayashi H; Nishitani Y; Ohmoto T; Toyokura Y; Uono K
    No To Shinkei; 1981 Mar; 33(3):301-9. PubMed ID: 7018522
    [No Abstract]   [Full Text] [Related]  

  • 64. Dopaminergic deficiency and delayed visual evoked potentials in humans.
    Bodis-Wollner I; Yahr MD; Mylin L; Thornton J
    Ann Neurol; 1982 May; 11(5):478-83. PubMed ID: 6125124
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Letter: Parkinson's disease and ascorbate.
    Dettman G
    Med J Aust; 1976 Jan; 1(5):131. PubMed ID: 1263962
    [No Abstract]   [Full Text] [Related]  

  • 66. Plasma levels of levodopa. Its main metabolites and carbidopa after conventional and slow release levodopa-carbidopa treatment in parkinsonian patients.
    Baraldo M; Zara G; Benetello P; Furlanut M
    Pharmacol Res; 1990; 22 Suppl 1():119-20. PubMed ID: 2284227
    [No Abstract]   [Full Text] [Related]  

  • 67. [Treatment of parkinsonian syndrome with Ro 8-0576].
    Bernales JV; Mere AF; Portillo R
    Rev Neuropsiquiatr; 1975 Jun; 38(2):65-73. PubMed ID: 1209053
    [No Abstract]   [Full Text] [Related]  

  • 68. Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients.
    Quaglieri CE; Celesia GG
    Eur Neurol; 1977; 15(1):34-9. PubMed ID: 852463
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levodopa-free periods ("drug holidays") in the management of parkinsonism.
    Klawans HL; Goetz CG; Tanner CM; Nausieda PA; Weiner WJ
    Adv Neurol; 1983; 37():33-43. PubMed ID: 6858778
    [No Abstract]   [Full Text] [Related]  

  • 70. The effect of dopaflex on the clinical picture and reaction time of parkinsonian patients.
    Antal J
    Ther Hung; 1974; 22(2):70-8. PubMed ID: 4419534
    [No Abstract]   [Full Text] [Related]  

  • 71. A quantitative study of the electroencephalographic response to levodopa treatment in parkinsonian patients.
    Yaar I; Shapiro MB
    Clin Electroencephalogr; 1983 Apr; 14(2):82-5. PubMed ID: 6851190
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
    Shoulson I; Chase TN
    Neuropharmacology; 1976 Jan; 15(1):25-7. PubMed ID: 768802
    [No Abstract]   [Full Text] [Related]  

  • 73. A comparison of levodopa treatment and task demands on visual evoked potentials in hemi-parkinsonism.
    Mintz M; Tomer R; Radwan H; Myslobodsky MS
    Psychiatry Res; 1982 Apr; 6(2):245-51. PubMed ID: 6953463
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Structure of psychomotor functions in parkinsonian patients during long-term treatment.
    Jacobi P; Fischer PA; Schneider E
    Adv Neurol; 1984; 40():279-83. PubMed ID: 6695604
    [No Abstract]   [Full Text] [Related]  

  • 75. Adult onset of stuttering as a presenting sign in a parkinsonian-like syndrome: a case report.
    Leder SB
    J Commun Disord; 1996; 29(6):471-7; quiz 477-8. PubMed ID: 8956103
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Sclerodermiform and poikilodermal syndrome observed during treatment with carbidopa and 5-hydroxytryptophan].
    Auffranc JC; Berbis P; Fabre JF; Garnier JP; Privat Y
    Ann Dermatol Venereol; 1985; 112(9):691-2. PubMed ID: 4091416
    [No Abstract]   [Full Text] [Related]  

  • 77. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy.
    Meadows GG; Pierson HF; Abdallah RM; Desai PR
    Cancer Res; 1982 Aug; 42(8):3056-63. PubMed ID: 7093952
    [No Abstract]   [Full Text] [Related]  

  • 78. [Initial experiences with Levodopa in the treatment of the Parkinsonian syndrome].
    Beteta E; Gonzales-Portillo MA; Voto Bernales J
    Rev Neuropsiquiatr; 1970 Jun; 33(2):136-45. PubMed ID: 5509274
    [No Abstract]   [Full Text] [Related]  

  • 79. [Changeable aspects in the epidemiology of Parkinson disease (analysis of 262 cases during a period of 9 years].
    Giménez-Roldán S; Martin Moro M; Mateo D; Cardenas A
    Rev Clin Esp; 1980 Jan; 156(1):25-30. PubMed ID: 7375683
    [No Abstract]   [Full Text] [Related]  

  • 80. Parkinsonism with neuroacanthocytosis.
    Peppard RF; Lu CS; Chu NS; Teal P; Martin WR; Calne DB
    Can J Neurol Sci; 1990 Aug; 17(3):298-301. PubMed ID: 2207884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.